EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors

Launched by GUANGXI MEDICAL UNIVERSITY · Sep 30, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment method called Endoscopic Ultrasound-Fine Needle Injection (EUS-FNI) for patients with nonfunctional pancreatic neuroendocrine tumors (pNETs). These tumors are a type of growth in the pancreas that doesn't produce hormones. The researchers want to see if EUS-FNI is a safe and effective option for patients who either do not want surgery or who are not suitable for surgery.

To participate in this trial, patients need to have been diagnosed with nonfunctional pNETs through specific tests. They should also be willing to give their consent to join the study. However, individuals with certain health issues, such as problems with blood clotting or serious heart and lung conditions, may not be eligible. If you join the trial, you can expect to undergo the EUS-FNI procedure, which is performed using a thin needle guided by ultrasound to deliver treatment directly to the tumor. This trial is currently recruiting participants, and both men and women between the ages of 65 and 104 are welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with NF-pNETs are evaluated by cytology or immunohistochemistry.
• • 2. Patients who refuse surgery or observation.
• • 3. Patients who have given their fully informed consent.
• Exclusion Criteria:
• • 1. Patients who are not suitable for EUS-FNI.
• • 2. Patients who have poor conditions including blood coagulation dysfunction, mental disorders, and mild or severe cardiorespiratory.